A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
Orchard sets US price tag for rare disease gene therapy Lenmeldy at $4.25M
Orchard Therapeutics’ ultra-rare disease drug Lenmeldy is vaulting to the list of most expensive drugs ever with a wholesale acquisition cost of $4.25 million for
March 21, 2024